Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of hydroxyeicosatetraenoic acid compounds to treat ophthalmic inflammatory disorders

Use of hydroxyeicosatetraenoic acid compounds to treat ophthalmic inflammatory disorders

US Patent 6825232 · Granted Nov 30, 2004

Estimated economic value: $77,870,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Fixation members, assemblies, and related systems and methods2023
RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of CAMP-relat2017
RNAi-mediated inhibition of histamine receptor H1-related conditions2017
High concentration olopatadine ophthalmic composition2017
RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-relat2016
RNAi-mediated inhibition of tumor necrosis factor α-related conditions2016
RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditio2016
RNAi-mediated inhibition of histamine receptor H1-related conditions2015
RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditio2014
High concentration olopatadine ophthalmic composition2014
RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-relat2014
RNAi-mediated inhibition of histamine receptor H1-related conditions2013